Related Experiment Video
Updated: Jun 27, 2025

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
Exploring inflammatory bowel disease therapy targets through druggability genes: a Mendelian randomization study
Shuangjing Zhu1, Yunzhi Lin1, Zhen Ding1
1Department of Hepatobiliary Surgery, Chaohu Hospital of Anhui Medical University, Hefei, China.
This study used Mendelian randomization to identify potential drug targets for inflammatory bowel disease (IBD) and its subtypes, Crohn's disease (CD) and ulcerative colitis (UC). Several genes were found to be associated with IBD risk and progression.
Area of Science:
- Genetics
- Pharmacology
- Gastroenterology
Background:
- Inflammatory bowel disease (IBD) encompasses incurable, recurrent intestinal inflammatory conditions.
- Mendelian randomization (MR) aids in identifying therapeutic targets for diseases like IBD.
Purpose of the Study:
- To identify potential therapeutic targets for IBD and its subtypes, ulcerative colitis (UC) and Crohn's disease (CD), using a drug-targeted MR approach.
- To evaluate the druggability of identified targets for potential therapeutic applications.
Main Methods:
- Two-sample MR was used to investigate gene-IBD relationships, with replication MR for validation.
- Summary data-based MR and Bayesian co-localization enhanced outcome robustness.
- Druggability estimation assessed the therapeutic potential of identified targets.
Main Results:
- Several genes were identified as potential therapeutic targets for IBD risk.
- GPBAR1, IL1RL1, PRKCB, and PNMT are associated with IBD risk.
- IL1RL1 showed a protective effect against CD risk, while GPX1, GPBAR1, and PNMT are linked to UC risk.
Conclusions:
- The study identified novel potential therapeutic targets for IBD and its subtypes.
- These findings offer new insights for developing therapeutic agents for IBD treatment.
More Related Videos
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids